BBA
TSHA icon

Baker Bros. Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Baker Bros. Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.9M Hold
4,004,756
– – 0.1% 58
2025
Q4 		$22M Hold
4,004,756
– – 0.13% 47
2025
Q3 		$13.1M Hold
4,004,756
– – 0.09% 58
2025
Q2 		$9.25M Hold
4,004,756
– – 0.09% 55
2025
Q1 		$5.57M Hold
4,004,756
– – 0.06% 57
2024
Q4 		$6.93M Hold
4,004,756
– – 0.07% 63
2024
Q3 		$8.05M Hold
4,004,756
– – 0.08% 60
2024
Q2 		$8.97M Hold
4,004,756
– – 0.11% 52
2024
Q1 		$11.5M Hold
4,004,756
– – 0.14% 46
2023
Q4 		$7.09M Buy
4,004,756
+1,500,000
+60% +$2.99M 0.08% 58
2023
Q3 		$7.92M Buy
+2,504,756
New +$4.68M 0.05% 52

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baker Bros. Advisors's TSHA Position: Q1 2026 in Review

Baker Bros. Advisors held its Taysha Gene Therapies (TSHA) position steady in Q1 2026 at 4,004,756 shares worth $17.9M. The position accounts for 0.1% of the portfolio, ranked #58.

Baker Bros. Advisors first reported a position in TSHA in Q3 2023 and has held it in 11 quarters since. The position peaked at $22M in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Baker Bros. Advisors held 4,004,756 shares of Taysha Gene Therapies worth $17.9M as of Q1 2026.
  • Baker Bros. Advisors left its Taysha Gene Therapies share count unchanged in Q1 2026.
  • Taysha Gene Therapies made up 0.1% of Baker Bros. Advisors's portfolio in Q1 2026, its #58 holding.
  • Baker Bros. Advisors first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 11 quarters since.
  • Baker Bros. Advisors's Taysha Gene Therapies position peaked at $22M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.